07 Jan 2001

Eremfat® 150 (Eremfat® 150/-300/-450/-600 Filmtabletten) - Deutschland

Updated: 07 Jan 2001

Eremfat® 150 | -300 | -450 | -600; -Sirup; -i.v. 300 mg | -600 mg

Tuberkulose (in Komb. mit anderen Tuberkulosemitteln). Zur Kombinationsbehandl. bei Lepra u. Buruli ulcus (Erreger: Mycobacterium leprae, bzw. M. ulcerans). Meningokokken- Meningitis-Prophylaxe.

Eremfat® 150 Description, Presentation and Dosage

Eremfat® 150 Description

Eremfat® 150 Drug Class Description

Einzelstoffe

Eremfat® 150 Drug Description

1 Filmtbl. enth.: Rifampicin 150 mg/300 mg/450 mg/600 mg.

Eremfat® 150 Generic Name

Eremfat® 150/-300/-450/-600 Filmtabletten

Eremfat® 150 Presentation

Eremfat® 150 Presentation

Eremfat® 150/-300/-450/-600; -Sirup; -i.v. 300 mg/-600 mg

Eremfat® 150 Manufacturer

Fatol

Related Learning Zones

CLL Knowledge Centre and CME

CLL Knowledge Centre and CME

The Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre contains useful information arranged within four main sections: ‘Disease Awareness’, ‘Events’, ‘Resources’, and 'CME'. Healthcare professionals will find information on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment and management options, an upcoming events calendar and an external links listing,

The CME activity ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been EACCME-accredited and awarded 1 CME credit. Test your knowledge by answering quiz questions based on patient case study scenarios.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The Cystic Fibrosis Knowledge Centre provides healthcare professionals with access to disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

Eremfat® 150 Dosage

Eremfat® 150 Adult Dosage

Poly(O-2-hydroxypropyl-O-methyl)cellulose, Croscarmellose-Natrium, Magnesiumstearat, Talkum, Farbstoffe: E 171, E 172, Crospovidon, Sorbitol.

Eremfat® 150 Child Dosage


Eremfat® Sirup Trockensirup
Zus.: 5 ml enth.: Rifampicin 100 mg.
Weit. Bestandteile: Saccharose 2,16 g, Natriumbenzoat (als Konservierungsmittel), Aromastoffe.

Eremfat® i.v. 300 mg/-600 mg Trockensubstanz u. Lösungsmittel
Zus.: 1 Inj.-Fl. enth.: Rifampicin-Natrium 308,2 mg mg/616,4 mg (entspr. 300 mg/600 mg Rifampicin).
Weit. Bestandteile: Natriumascorbat 5 mg/10 mg.

Eremfat® 150 Elderly Dosage

5 ml entspr. 0,18 BE.

Eremfat® 150 Precautions, Reactions and Contraindications

Eremfat® 150 Special Precautions

Eremfat® 150 Special Precautions

R 15

Eremfat® 150 Adverse Reactions

Eremfat® 150 Adverse Reactions

R 15

Related Drugs - Tropical Medicine

Back to top